Page 48 - GTM-3-1
P. 48

Global Translational Medicine                                     Personalized, multi-omics disease detection




             A                              B                                 E





















             C                             D











            Figure 2. A schematic representation of the envisioned future of healthcare and drug discovery, where wearable technology and multi-omics characterization
            are fused to provide personalized, real-time health assessments and interventions. (A) The patient is monitored by wearable devices that unobtrusively track
            vital signs and physiological parameters. (B) An automated alert system triggers a response when significant deviations occur, and (C) biosamples, which
            have been sampled continuously and regularly from the beginning, are collected for (D) multi-omics characterization, which provides a unique molecular
            profile of the patient. All data is summarized in a legible integrated personalized report. (E) The insights gleaned from the multi-omics characterization
            serve as a powerful tool for healthcare providers, triggering additional measures, enabling early detection and tailored therapeutic interventions. The
            illustration was created with BioRender.com.

            7.1. Continuous health monitoring                  variability, body temperature, oxygen saturation or even sleep
                                                                         86
            The patient is seamlessly monitored by wearable devices   disturbances.  The deviation could also constitute a general
            that unobtrusively monitor his vital signs (such as heart rate,   health decline, possibly due to drug-induced liver toxicity or
            blood pressure, oxygenation levels, blood glucose, nitrogen   other adverse side effects, particularly those that are unexpected.
            levels, or others of relevance) and physiological parameters   If the deviation is substantial and cannot be explained by dietary
            (such  as  motion  and  sleep  patterns).  Supplementing  the   choices or any other self-reported incidents from the electronic
                                                85
            wearable tech data are an electronic diary  where the   diary, the system would trigger a response.
            patient logs food and supplements, intake of other drugs   7.3. Sample collection and transport
            (such as prescribed, over-the-counter, or recreational)
            and any self-reported ailments (e.g., the common cold   In response to these alerts, a courier will be dispatched to
            or a sprained ankle). These wearables are equipped with   the individual’s location to collect stored biosamples, such
            advanced sensors and machine learning algorithms that   as dried blood spots, which have been routinely collected
            establish personalized health baselines. They continuously   on  a  daily  or  weekly  basis  by  the  participant  themself.
            track the participant’s health metrics and generate alerts   Alternatively, a micro sampler device of the type used in
            when significant deviations occur.                 iPOP research could be adapted for this purpose. These
                                                               samples serve as a snapshot of the individual’s physiology and
            7.2. Automated alert system                        molecular composition during the period of deviation as well
            When a deviation from the established baseline is detected,   as for the baseline prior to the deviation. Dried blood spots
            an automated alert is sent to a central computer program,   can be easily obtained with a finger prick by the patient and
            which assesses the data. For a sickle cell disease patient, this   stored on a piece of paper at room temperature. Of course,
            could include, but not be limited to, heart rate and heart rate   pre- and post-assessment of analyte stability are pivotal.


            Volume 3 Issue 1 (2024)                         8                        https://doi.org/10.36922/gtm.2357
   43   44   45   46   47   48   49   50   51   52   53